Beta
Aprepitant
medication Under reviewA substance P/neurokinin 1 (NK1) receptor antagonist used to prevent chemotherapy-induced nausea and vomiting.
Research summary
Human research on aprepitant is extensive but almost entirely focused on patients receiving emetogenic chemotherapy or undergoing surgery, and on its pharmacokinetics and formulation comparisons in healthy volunteers. Healthy-subject trials primarily assess bioequivalence, tolerability, and safety rather than performance or wellness benefits. The evidence consistently supports aprepitant as a safe and effective component of antiemetic regimens for preventing chemotherapy-induced and postoperative nausea and vomiting, with large randomized controlled trials and meta-analyses demonstrating strong efficacy and acceptable safety profiles. In healthy adults, short-term exposure in pharmacokinetic and formulation studies shows good tolerability, but there is no evidence supporting any performance, cognitive, metabolic, or longevity benefits for healthy people.
Reported Benefits
No reports yet
Be the first to report this effect and help the community.
Add Aprepitant to your stack to report effects
Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial
H. Kazama, T. Kawamura, et al.
The Oral NK1 Antagonist Aprepitant, Given with Standard Antiemetics, Provides Protection Against Nausea and Vomiting Over Multiple Cycles of Cisplatin-Based Chemotherapy
P. J. Hesketh, J. S. Grunberg, et al.
Efficacy and safety of Aprepitant-containing triple therapy for the prevention and treatment of chemotherapy-induced nausea and vomiting: A meta-analysis.
Y. Zhang, L. Li, et al.
No reports yet
Be the first to report this effect and help the community.
Add Aprepitant to your stack to report effects
Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial
H. Kazama, T. Kawamura, et al.
The Oral NK1 Antagonist Aprepitant, Given with Standard Antiemetics, Provides Protection Against Nausea and Vomiting Over Multiple Cycles of Cisplatin-Based Chemotherapy
P. J. Hesketh, J. S. Grunberg, et al.
Efficacy and safety of Aprepitant-containing triple therapy for the prevention and treatment of chemotherapy-induced nausea and vomiting: A meta-analysis.
Y. Zhang, L. Li, et al.
No side effects tracked yet
No side effects have been reported by studies or users for this habit yet.
Related health conditions
Research showing how this habit affects specific health conditions. Always consult healthcare professionals.
May Help With
Coronary artery disease or other cardiac conditions
RE: Aprepitant use during chemotherapy and association with survival in women with early breast cancer.
J. C. Christiansen, N. K. Nielsen, et al.
Research (4 studies)
RE: Aprepitant use during chemotherapy and association with survival in women with early breast cancer.
J. C. Christiansen, N. K. Nielsen, et al.
Efficacy and safety of Aprepitant-containing triple therapy for the prevention and treatment of chemotherapy-induced nausea and vomiting: A meta-analysis.
Y. Zhang, L. Li, et al.
Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial
H. Kazama, T. Kawamura, et al.
The Oral NK1 Antagonist Aprepitant, Given with Standard Antiemetics, Provides Protection Against Nausea and Vomiting Over Multiple Cycles of Cisplatin-Based Chemotherapy
P. J. Hesketh, J. S. Grunberg, et al.
Community updates
No updates yet for this supplement.
Be the first to share your experience!